Hypometabolism, Alzheimer's Disease, and Possible Therapeutic Targets: An Overview.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms and theory without systematic search methodology or original empirical data
PubMed 37626828 · doi:10.3390/cells12162019
What was done
This narrative review synthesizes literature on cerebral glucose transport across the blood-brain barrier (via GLUT and SGLT transporters), energy metabolism, and brain hypometabolism. It focuses on mechanisms linking brain insulin resistance, age-dependent mitochondrial dysfunction, and neurodegenerative conditions, specifically Alzheimer's disease and related neurological disorders.
What was found
The abstract reports no quantitative data or numerical effect sizes. It describes cerebral glucose hypometabolism as an early feature in Alzheimer's disease, Parkinson's disease, epilepsy, traumatic brain injury, and schizophrenia, noting literature suggesting that metabolic decline precedes brain atrophy and clinical symptom manifestation rather than merely resulting from neuronal loss.
Why it matters
Framing glucose hypometabolism as an early or prodromal driver rather than a late downstream consequence of neuronal death supports investigating cerebral energy metabolism and insulin signaling pathways as early therapeutic targets.
Limits
This is a narrative review with no systematic search protocol, inclusion criteria, quality appraisal, or meta-analytic synthesis. The abstract provides no original human data, sample sizes, or quantitative findings to verify the clinical efficacy of any proposed therapeutic targets.
Cited by
- supports In dementia, brain glucose transport and metabolism face increased resistance and diminished energy utilization.